Christopher Holliman, Ph.D. is the Senior Director of Pfizer’s Global, Small-Molecule, Bioanalytical Research Group. Chris’ group provides drug quantification from biomatrices in support of Pfizer’s global, small-molecule, discovery and development portfolios. His group’s efforts encompass global sample logistics, high-throughput in vitro, non-regulated and regulated bioanalysis, and their associated outsourcing. The group’s current interests include the collection and subsequent analysis of micro-samples, supercritical fluid and micro- to nano-flow chromatography, and the application of full-scan high-resolution mass spectrometry in the non-regulated and regulated bioanalytical environments. One recent area of bioanalytical focus has been the development and validation of assays to support in vivo studies of therapeutic-encapsulated, polymeric nanoparticles. Chris has led regulated and non-regulated small-molecule bioanalytical groups at Pfizer for the last 20 years. Prior to this he developed and validated bioanalytical assays for PharmaKinetics; a contract research organization. He received his Ph.D. in Analytical Chemistry from the University of Nebraska, and served as a National Research Council Postdoctoral Fellow at the Naval Research Laboratory in Washington D.C.
Tuesday, November 5
10:00 AM – 10:30 AM